Orsema 0.5 mg/0.375 ml (SC Injection)
0.5 mg pre-filled syringe: ৳ 600.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Semaglutide |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- Adjunct to diet and exercise for type 2 diabetes mellitus
- Reduction of major adverse cardiovascular events in type 2 diabetes mellitus
- Chronic weight management for obesity
- Reduced appetite for weight management
Pharmacology
- GLP-1 analogue
- Stimulates insulin secretion
- Lowers glucagon secretion
- Reduces blood glucose
- Delays gastric emptying
- Reduces body weight and fat mass
Dosage & Administration
- Initial starter dose of 3 mg once daily
- Maintenance dose of 7 mg once daily
- Additional glycemic control with 14 mg once daily
- Injection starting dose of 0.25 mg once weekly
- Injection maintenance dose escalation to 0.5 mg once weekly and then to 1 mg once weekly
- Decrease and increase doses for tolerance
- Subcutaneous injection in abdomen, thigh, or upper arm
Interaction
- Delays gastric emptying
- Potential impact on absorption of concomitant oral medications
Contraindications
- Hypersensitivity to active substance or excipients
Side Effects
- Hypoglycemia with insulin or sulfonylurea
- Gastrointestinal disorders
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Constipation
- Allergic reactions
- Injection site reactions
- Lipodystrophy
- Pruritus
- Rash
Pregnancy & Lactation
- Not to be used during pregnancy
- Discontinue at least 2 months before planned pregnancy
- Not to be used during breastfeeding
Precautions & Warnings
- Not for type 1 diabetes mellitus or diabetic ketoacidosis
- Prompt discontinuation if pancreatitis suspected
- Monitoring for diabetic retinopathy
- No established safety and efficacy for children and adolescents below 18 years
- No dose adjustment based on age or renal impairment
- Not recommended for end-stage renal disease
- No dose adjustment for hepatic impairment
Overdose Effects
- Reported overdose up to 4 mg in a single dose and in a week
- Most commonly reported adverse reaction was nausea
- No specific antidote for overdose
- Supportive treatment for clinical signs and symptoms
- Adjustment in existing metformin/thiazolidinedione therapy
- Reduction in the dose of sulfonylurea or insulin
- Missed dose administration and schedule resumption
Therapeutic Class
- GLP-1 receptor agonists
Storage Conditions
- Store at 2°C to 8°C (in a refrigerator)
- Do not freeze
- Keep out of reach of children